TrialJAMA neurology2021

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.

Reisa Sperling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.